Known targets — ChEMBL curated mechanism
FLT1FLT3FLT4KDRKITMETPDGFRAPDGFRBTEK
The experimentally established mechanism targets of Foretinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 16/20 | 0.99 |
| ▸ | KDR known ✓ | P35968 | 6/20 | 0.99 |
| ▸ | FLT3 known ✓ | P36888 | 5/20 | 0.99 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.99 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.99 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.99 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.99 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.99 |
| ▸ | TEK known ✓ | Q02763 | 1/20 | 0.99 |
| ▸ | AXL | P30530 | 3/20 | 0.99 |
| ▸ | RET | P07949 | 2/20 | 0.99 |
| ▸ | PLK4 | O00444 | 1/20 | 0.99 |
| ▸ | STK25 | O00506 | 1/20 | 0.99 |
| ▸ | CIT | O14578 | 1/20 | 0.99 |
| ▸ | AURKA | O14965 | 1/20 | 0.99 |
| ▸ | CHUK | O15111 | 1/20 | 0.99 |
| ▸ | MUSK | O15146 | 1/20 | 0.99 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.99 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.99 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Foretinib SCHEMBL371804 | 0.99 | MET (1.00) | METKDRFLT3AXLRET | |
| Foretinib SCHEMBL29358674 | 0.99 | MET (1.00) | METKDRFLT3AXLRET | |
| Foretinib SCHEMBL30498609 | 0.99 | MET (1.00) | METKDRFLT3AXLRET | |
| SCHEMBL29693444 | 0.99 | MET (1.00) | METKDRFLT3AXLRET | |
| SCHEMBL372153 | 0.99 | MET (1.00) | METKDRFLT3AXLRET | |
| Foretinib SCHEMBL958129 | 0.97 | MET (0.95) | METKDRFLT3AXLRET | |
| SCHEMBL14742522 | 0.94 | MET (0.91) | METKDRFLT3AXLRET | |
| SCHEMBL15003127 | 0.94 | MET (0.91) | METKDRFLT3AXLRET | |
| SCHEMBL19370040 | 0.94 | MET (0.91) | METKDRFLT3AXLRET | |
| SCHEMBL16070054 | 0.94 | MET (0.90) | METKDRFLT3AXLRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130143881-A1 | Hydrated Crystalline Forms of N-[3-fluoro-4-(oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. (US) | 2013-06-06 | — | — | US | claimed |
| EP-2545038-A1 | HYDRATED CRYSTALLINE FORMS OF N-[3-FLUORO-4-({6-(METHYLOXY)-7-[(3-MORPHOLIN-4-YLPROPYL)OXY]-QUINOLIN-4-YL}OXY)PHENYL]-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE | Exelixis, Inc. (US) | 2013-01-16 | — | — | EP | claimed |
| WO-2011112896-A1 | HYDRATED CRYSTALLINE FORMS OF N-[3-FLUORO-4-({6-(METHYLOXY)-7-[(3-MORPHOLIN-4-YLPROPYL)OXY]-QUINOLIN-4-YL}OXY)PHENYL]-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE | EXELIXIS, INC (US) | 2011-09-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143881-A1 | Hydrated Crystalline Forms of N-[3-fluoro-4-(oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | TP53, CDC25A, CDC25C | MET 1453/4885KDR 2855/4885FLT3 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.